Claims

1. A compound of the formula:



(I)

wherein wherein X is selected from the group consisting of: N, CH, CCF_3, and $C(C_{1-12}$ aliphatic);

Y is C or N, with the proviso that when Y is N, R^1 is absent, and Z, A and D are each C;

Z is C or N, with the proviso that when Z is N, R^2 is absent, and Y, A and D are each C;

A is C or N, with the proviso that when A is N, R^3 is absent, and Y, Z and D are each C;

D is C or N, with the proviso that when D is N, then Y, Z and A are each C;

with the further proviso that Y, Z, A and D do not simultaneously all represent C;

R^1 is selected from the group consisting of: hydrogen, C_{1-12} aliphatic, thiol, hydroxy, hydroxy-C_{1-12} aliphatic, Aryl, Aryl-C_{1-12} aliphatic, R^6-Aryl-C_{1-12} aliphatic, Cyc, Cyc-C_{1-8} aliphatic, Het, Het-C_{1-12} aliphatic, C_{1-12} alkoxy, Aryloxy, amino, C_{1-12} aliphatic amino, di-C_{1-12} aliphatic amino, di-C_{1-12} aliphatic aminocarbonyl, di-C_{1-12} aliphatic aminosulfonyl, C_{1-12} alkoxycarbonyl, halogen, cyano, sulfonamide and nitro, where R^6, Aryl, Cyc and Het are as defined below;

R^2 is selected from the group consisting of: hydrogen, C_{1-12} aliphatic, N-hydroxyimino-C_{1-12} aliphatic, C_{1-12} alkoxy, hydroxy-C_{1-12} aliphatic, C_{1-12} alkoxycarbonyl, carboxyl C_{1-12} aliphatic, Aryl, R^6-Aryl-oxycarbonyl, R^6-oxycarbonyl-Aryl, Het, aminocarbonyl, C_{1-12} aliphatic-aminocarbonyl, Aryl-C_{1-12} aliphatic-aminocarbonyl, R^6-Aryl-C_{1-12} aliphatic-aminocarbonyl, Het-C_{1-12} aliphatic-aminocarbonyl, hydroxy-C_{1-12} aliphatic-aminocarbonyl, C_{1-12}-alkoxy-C_{1-12} aliphatic-aminocarbonyl, C_{1-12} alkoxy-C_{1-12} aliphatic-amino, di-C_{1-12} aliphatic amino, di-C_{1-12} aliphatic aminocarbonyl, di-C_{1-12} aliphatic aminosulfonyl, halogen, hydroxy, nitro, C_{1-12} aliphatic-sulfonyl, aminosulfonyl and C_{1-12} aliphatic-aminosulfonyl, where R^6 Aryl and Het are as defined below;

R^1 and R^2 are optionally joined to form a fused ring selected from the group as defined for Het below, and said fused ring is optionally substituted by one or more substituents selected from the group consisting of: C_{1-12} aliphatic, halogen, nitro, cyano, C_{1-12} alkoxy, carbonyl-C_{1-12} alkoxy and oxo;

R^3 is selected from the group consisting of: hydrogen, C_{1-12} aliphatic, hydroxy, hydroxy C_{1-12} aliphatic, di-C_{1-12} aliphatic amino, di-C_{1-12} aliphatic aminocarbonyl, di-C_{1-12} aliphatic aminosulfonyl, C_{1-12} alkoxy, Aryl, Aryloxy, hydroxy-Aryl, Het, hydroxy-Het, Het-oxy and halogen, where Aryl and Het are as defined below;

R^2 and R^3 are optionally joined to form a fused ring selected from the group as defined for Het below, and said fused ring is optionally substituted by C_{1-6} aliphatic and/or C_{1-6} aliphatic-carbonyl;

R^4 is selected from the group consisting of: sulfonic acid, C_{1-12} aliphatic-sulfonyl, sulfonyl-C_{1-12} aliphatic, C_{1-12} aliphatic-sulfonyl-C_{1-6} aliphatic, C_{1-6} aliphatic-amino, R^7-sulfonyl, R^7-sulfonyl-C_{1-12} aliphatic, R^7-aminosulfonyl, R^7-aminosulfonyl-C_{1-12} aliphatic, R^7-sulfonylamino, R^7-sulfonylamino-C_{1-12} aliphatic, aminosulfonylamino, di-C_{1-12} aliphatic amino, di-C_{1-12} aliphatic aminocarbonyl, di-C_{1-12} aliphatic aminosulfonyl, di-C_{1-12} aliphatic amino, di-

C_{1-12} aliphatic aminocarbonyl, di-C_{1-12} aliphatic aminosulfonyl-C_{1-12} aliphatic, $(R^8)_{1-3}$-Arylamino, $(R^8)_{1-3}$-Arylsulfonyl, $(R^8)_{1-3}$-Aryl-aminosulfonyl, $(R^8)_{1-3}$-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino and aminoiminoaminosulfonyl, where R^7, R^8, Aryl and Het are as defined below;

R^5 is hydrogen or R^4 and R^5 are optionally joined to form a fused ring selected from the group as defined for Het below, and said fused ring is optionally substituted by one or more substituents selected from the group consisting of: C_{1-12} aliphatic, oxo and dioxo;

R^6 is selected from the group consisting of: C_{1-12} aliphatic, hydroxy, C_{1-12} alkoxy and halogen;

R^7 is selected from the group consisting of: hydrogen, C_{1-12} aliphatic, C_{1-12} alkoxy, hydroxy-C_{1-12} alkoxy, hydroxy-C_{1-12} aliphatic, carboxylic acid, C_{1-12} aliphatic-carbonyl, Het, Het-C_{1-12}-aliphatic, Het-C_{1-12}-alkoxy, di-Het-C_{1-12}-alkoxy Aryl, Aryl-C_{1-12}-aliphatic, Aryl-C_{1-12}-alkoxy, Aryl-carbonyl, C_{1-18} alkoxyalkoxyalkoxyalkoxyaliphatic and hydroxyl, where Het and Aryl are as defined below;

R^8 is selected from the group consisting of: hydrogen, nitro, cyano, C_{1-12} alkoxy, halo, carbonyl-C_{1-12} alkoxy and halo-C_{1-12} aliphatic;

Aryl is selected from the group consisting of: phenyl, naphthyl, phenanthryl and anthracenyl;

Cyc is selected from the group consisting of: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, and optionally has one or more degrees of unsaturation;

Het is a saturated or unsaturated heteroatom ring system selected from the group consisting of: benzimidazole, dihydrothiophene, dioxin, dioxane, dioxolane, dithiane, dithiazine, dithiazole, dithiolane, furan, imidazole, isoquinoline, morpholine, oxazole, oxadiazole, oxathiazole, oxathiazolidine, oxazine, oxadiazine, piperazine, piperadine, pyran, pyrazine, pyrazole,

pyridine, pyrimidine, pyrrole, pyrrolidine, quinoline, tetrahydrofuran, tetrazine, thidiazine, thiadiazole, thiatriazole, thiazine, thiazole, thiomorpholine, thiophene, thiopyran, triazine and triazole;

and the salts, esters, amides, carbamates, solvates, polymorphs, hydrates, polymorphs, affinity reagents and/or prodrugs thereof.

2. The compound of claim 1 wherein X is selected from the group consisting of: N, CH and CCH_3.

3. The compound of claim 1 where X is CH.

4. The compound of claim 1 where X is CCH_3.

5. The compound of claim 1 where X is N.

6. The compound of claim 1 where Y is C.

7. The compound of claim 1 where Y is N and Z, A and D are each C.

8. The compound of claim 1 where Z is C.

9. The compound of claim 1 where Z is N and Y, A and D are each C.

10. The compound of claim 1 where A is C.

11. The compound of claim 1 where A is N and Y, Z and D are each C.

12. The compound of claim 1 where D is C.

13. The compound of claim 1 where D is N and Y, Z and A are each C.

14. The compound of claim 1 where R^1 is selected from the group consisting of: hydrogen, halogen, amide, nitro, lower alkyl, hydroxy, hydroxyalkyl, pyrimidineloweralkyl, loweralkoxycarbonyl, cyclic loweralkyl, hydroxyphenylloweralkyl, phenoxy, alkoxy and pyrazole.

15. The compound of claim 1 where R^1 is hydrogen or methyl.

16. The compound of claim 1 where R^1 is hydrogen.

17. The compound of claim 1 where R^1 is fused with R^2 to form a fused ring selected from the group consisting of: thiazole, pyrazole, triazole, halogen-substituted diazole, acyl substituted pyrrole and pyridine.

18. The compound of claim 1 where R^1 is fused with R^2 for form fused thiazole or fused pyridine.

19. The compound of claim 1 where R^2 is selected from the group consisting of: hydrogen, halogen, sulfate, amine, quaternary amine, amide, ester, phenyl, alkoxy, aminosulfonyl, lower alkyl sulfonyl, furanyl lower alkyl amide, pyridinyl lower alkyl amide, alkoxy-substituted phenyl lower alkyl amide, morpholino lower alkyl amide, imidazolyl lower alkyl amide, hydroxy lower alkyl amide, alkoxy lower alkyl amide, lower alkyl amide, lower alkyl sulfonamide, lower alkyl hydroxy substituted amino, nitro, halogen-substituted phenoxycarbonyl and triazole and oxazole rings.

20. The compound of claim 1 where R^3 is selected from the group consisting of: hydrogen, lower alkyl, hydroxy lower alkyl, halogen, phenoxy and alkoxy.

21. The compound of claim 1 where R^2 is selected from the group consisting of: hydrogen, phenyl, 2-furanyl, 3-thiophenyl, bromo and carbethoxy.

22. The compound of claim 1 where R^2 is fused with R3 to form a fused ring selected from the group consisting of: oxazole, pyrrole, and dioxolane, which fused ring is optionally substituted by lower alkyl or lower alkyl carbonyl, and which fused ring is optionally a hetero ring having nitrogen as the heteroatom and forming a quaternary ammonium salt ionically bonded with a halogen atom.

23. The compound of claim 1 where R^3 is hydrogen or chloro.

24. The compound of claim 1 where R^3 is hydrogen.

25. The compound of claim 1 where R^4 is selected from the group consisting of: sulfonylamino, sulfonylaminoamino, lower alkyl sulfonylamino, lower alkylsulfonyl lower alkyl, alkoxysulfonylamino, phenylcarbonylsulfonylamino, phenoxysulfonyl, hydroxy lower alkylsulfonylamino, hydroxy lower alkylsulfonylamino lower alkyl, alkyl, phenylsulfonylamino (optionally substituted by halogen-substituted lower alkyl), aminoiminosulfonylamino, alkylsulfonylaminoalkyl, pyridinyl lower alkyl sulfonylamino, benzamideazolesulfonylamino, pyridylsulfonylamino, pyrimidinylsulfonylamino, thiadiazolylsulfonylamino (optionally substituted by lower alkyl), thiazolesulfonylamino, hydroxyalkoxyalkylsulfonylamino and 4'-$SO_2NH[(CH_2)_2O]_4CH_3$.

26. The compound of claim 1 where R^4 is selected from the group consisting of: 2-pyridine sulfonylamino, 4-pyridine sulfonylamino, hydroxy n-butyl sulfonylamino, methylsulfonylaminomethylene, sulfonyldimethylamino, fused 1,2-pyrazole and sulfonylamino.

27. The compound of claim 1 where R^4 is sulfonylamino or fused 1,2-pyrazole.

28. The compound of claim 1 where R^4 is fused with R^5 to form a fused ring selected from the group consisting of imidazole, triazole, cyclic sulfonylamino and thiaphene, where said fused ring is optionally disubstituted on the sulfur heteroatom by oxo.

29. The compound of claim 1 where R^5 is hydrogen.

30. The compound of claim 1 where R^6 is selected from the group consisting of: hydrogen, C_{1-6} aliphatic, hydroxy, C_{1-6} alkoxy and halogen.

31. The compound of claim 1 where R^6 is selected from the group consisting of: hydroxy, C_{1-6} alkoxy and halogen.

32. The compound of claim 1 where R^8 is hydrogen or halo C_{1-6} aliphatic.

33. The compound of claim 1 where R^8 is trifluoromethyl.

34. A compound of formula (I) as claimed in claim 1

wherein X is selected from the group consisting of: N, CH and C(C1-6 aliphatic);

Y is C or N, with the proviso that when Y is N, R1 is absent, and Z, A and D are each C;

Z is C or N, with the proviso that when Z is N, R2 is absent, and Y, A and D are each C;

A is C or N, with the proviso that when A is N, R3 is absent, and Y, Z and D are each C;

D is C or N, with the proviso that when D is N, then Y, Z and A are C;

with the further proviso that Y, Z, A and D do not simultaneously all represent C;

R1 is selected from the group consisting of: hydrogen, C1-6 aliphatic, hydroxy-C1-6 aliphatic, Aryl-C1-6 aliphatic, R6-Aryl-C1-6 aliphatic, Cyc-C1-6 aliphatic, Het-C1-6 aliphatic, C1-6 alkoxy, Aryloxy, aminocarbonyl, di-C1-6 aliphatic amino, di-C1-6 aliphatic aminocarbonyl, di-C1-6 aliphatic aminosulfonyl, C1-6 alkoxycarbonyl, halogen and nitro, where R6, Aryl, Cyc and Het are as defined below;

R2 is selected from the group consisting of: hydrogen, C1-6 aliphatic, R7-C1-6 aliphatic, C1-6alkoxy, hydroxy-C1-6 aliphatic, C1-6 alkoxycarbonyl, carboxyl C1-6 aliphatic, Aryl, R6-Aryl-oxycarbonyl, R6-oxycarbonyl-Aryl, Het, aminocarbonyl, C1-6 aliphatic-aminocarbonyl, Aryl-C1-6 aliphatic-aminocarbonyl, R6-Aryl-C1-6 aliphatic-aminocarbonyl, Het-C1-6 aliphatic-aminocarbonyl, hydroxy-C1-6 aliphatic-aminocarbonyl, C1-6-alkoxy-C1-6 aliphatic-aminocarbonyl, C1-6 alkoxy-C1-6 aliphatic-amino, di-C1-6 aliphatic amino, di-C1-6 aliphatic aminocarbonyl, di-C1-6 aliphatic aminosulfonyl, halogen, hydroxy, nitro, sulfo, C1-6 aliphatic-sulfonyl, aminosulfonyl, C1-6 aliphatic-aminosulfonyl and quaternary ammonium, where R6, R7, Aryl and Het are as defined below;

R1 and R2 are optionally joined to form a fused ring selected from the group as defined for Het below, and said fused ring is optionally substituted by halogen and/or oxo;

R3 is selected from the group consisting of: hydrogen, C1-6 aliphatic, hydroxy, hydroxy C1-6 aliphatic, di-C1-6 aliphatic amino, di-C1-6 aliphatic aminocarbonyl, di-C1-6 aliphatic aminosulfonyl, C1-6 alkoxy, Aryl, Aryloxy, hydroxy-Aryl, Het, hydroxy-Het, Het-oxy and halogen, where Aryl and Het are as defined below;

R2 and R3 are optionally joined to form a fused ring selected from the group as defined for Het below, and said fused ring is optionally substituted by C1-6 aliphatic or C1-6 aliphatic-carbonyl;

R4 is selected from the group consisting of: sulfonic acid, C1-12 aliphatic-sulfonyl, sulfonyl-C1-12 aliphatic, C1-12 aliphatic-sulfonyl-C1-6 aliphatic, C1-6 aliphatic-amino, R7-sulfonyl, R7-sulfonyl-C1-12 aliphatic, R7-aminosulfonyl, R7-aminosulfonyl-C1-12 aliphatic, R7-sulfonylamino, R7-sulfonylamino-C1-12 aliphatic, aminosulfonylamino, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl; di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl-C1-12 aliphatic, (R8)1-3-Arylamino, (R8)1-3-Arylsulfonyl, (R8)1-3-Aryl-aminosulfonyl, (R8)1-3-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl , aminoiminoamino and aminoiminoaminosulfonyl, where R7, R8, Aryl and Het are as defined below;

R5 is hydrogen;

R4 and R5 are optionally joined to form a fused ring selected from the group as defined for Het below, and said fused ring is optionally substituted by oxo or dioxo;

R6 is selected from the group consisting of: hydrogen, C1-6 aliphatic, hydroxy, C1-6 alkoxy and halogen;

R7 is selected from the group consisting of: hydrogen, C1-12 aliphatic, C1-12 alkoxy, hydroxy-C1-12 alkoxy, hydroxy-C1-12 aliphatic, carboxylic acid, C1-12 aliphatic-carbonyl, Het, Het-C1-12-aliphatic, Het-C1-12-alkoxy, di-Het-C1-12-alkoxy Aryl, Aryl-C1-12-aliphatic, Aryl-C1-12-alkoxy, Aryl-carbonyl, C1-18 alkoxyalkoxyalkoxyalkoxyaliphatic and hydroxyl, where Het and Aryl are as defined below;

R8 is hydrogen and/or halo-C1-6 aliphatic;

Aryl is phenyl or naphthyl;

Cyc is selected from the group consisting of: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, and optionally has one or more degrees of unsaturation;

Het is a saturated or unsaturat d heteroatom ring system selected from the group consisting of: benzimidazole, dihydrothiophene, dioxin, dioxane, dioxolane, dithiane, dithiazine, dithiazole, dithiolane, furan, imidazole, morpholine, oxazole, oxadiazole, oxathiazole, oxathiazolidine, oxazine, oxadiazine, piperazine, piperadine, pyran, pyrazine, pyrazole, pyridine, pyrimidine, pyrrole, pyrrolidine, tetrahydrofuran, tetrazine, thiadiazine, thiadiazole, thiatriazole, thiazine, thiazole, thiomorpholine, thiophene, thiopyran, triazine and triazole; and

the salts, esters, amides, carbamates, solvates, polymorphs, hydrates, affinity reagents and/or prodrugs thereof.

35. A compound of formula (I) as claimed in claim 1

wherein X is selected from the group consisting of: N, CH and CCH_3;

Y is C or N, with the proviso that when Y is N, R^1 is absent, and Z, A and D are each C;

Z is C or N, with the proviso that when Z is N, R^2 is absent, and Y, A and D are each C;

A is C or N, with the proviso that when A is N, R^3 is absent, and X, Y and D are each C;

D is C or N, with the proviso that when D is N, then Y, Z and A are each C;

with the further proviso that Y, Z, A and D do not simultaneously all represent C;

R^1 is selected from the group consisting of: hydrogen, C_{1-6} aliphatic, hydroxy-C_{1-6} aliphatic, di-C_{1-6} aliphatic amino, di-C_{1-6} aliphatic aminocarbonyl, di-C_{1-6} aliphatic aminosulfonyl, Aryl-C_{1-6} aliphatic, R^6-Aryl-C_{1-6} aliphatic, Cyc-C_{1-6} aliphatic, Het-C_{1-6} aliphatic, C_{1-6} alkoxy, Aryloxy, aminocarbonyl, C_{1-6} alkoxycarbonyl, halogen and nitro, where R^6, Aryl, Cyc and Het are as defined below;

R^2 is selected from the group consisting of: hydrogen, C_{1-6} aliphatic, N-hydroxyimino-C_{1-6} aliphatic, C_{1-6}alkoxy, C_{1-6} alkoxycarbonyl, Aryl, R^6-Aryloxycarbonyl, Het, aminocarbonyl, C_{1-6} aliphatic aminocarbonyl, Aryl-C_{1-6} aliphatic aminocarbonyl, R^6-Aryl-C_{1-6} aliphatic aminocarbonyl, Het-C_{1-6} aliphatic aminocarbonyl, di-C_{1-6} aliphatic amino, di-C_{1-6} aliphatic aminocarbonyl, di-C_{1-6} aliphatic aminosulfonyl, hydroxy-C_{1-6} aliphatic aminocarbonyl, C_{1-6}-alkoxy-C_{1-6} aliphatic aminocarbonyl, C_{1-6} alkoxy-C_{1-6} aliphatic amino, halogen, hydroxy, nitro, C_{1-6} aliphatic sulfonyl, aminosulfonyl and C_{1-6} aliphatic aminosulfonyl, where R^6, Aryl and Het are as defined below;

R^1 and R^2 are optionally joined to form a fused ring selected from the group as defined for Het below, and said fused ring is optionally substituted by halogen and/or oxo;

R^3 is selected from the group consisting of: hydrogen, C_{1-6} aliphatic, hydroxy, hydroxy C_{1-6} aliphatic, di-C_{1-6} aliphatic amino, di-C_{1-6} aliphatic aminocarbonyl, di-C_{1-6} aliphatic aminosulfonyl C_{1-6} alkoxy, Aryloxy, Het and halogen, where Aryl and Het are as defined below;

R^2 and R^3 are optionally joined to form a fused ring selected from the group as defined for Het below, and said fused ring is optionally substituted by C_{1-6} alkyl and/or C_{1-6} alkylcarbonyl;

R^4 is selected from the group consisting of: R^7-sulfonyl, R^7-sulfonyl C_{1-6}-aliphatic, C_{1-6} aliphatic sulfonyl-C_{1-6} aliphatic, R^7-aminosulfonyl, di-C_{1-6} aliphatic amino, di-C_{1-6} aliphatic aminocarbonyl, di-C_{1-6} aliphatic aminosulfonyl, di-C_{1-6} aliphatic aminosulfonyl-C_{1-6} aliphatic, R^7-aminosulfonyl C_{1-6} aliphatic, aminosulfonylamino, R^7-C_{1-6} aliphatic aminosulfonyl-C_{1-6} aliphatic, Aryl, Het, R^8-Aryl-aminosulfonyl, Het-aminosulfonyl and aminoiminoaminosulfonyl, where R^7, R^8, Aryl and Het are as defined below;

R^5 is hydrogen;

R^4 and R^5 are optionally joined to form a fused ring selected from the group as defined for Het below, and said used ring is optionally substituted by oxo or dioxo;

R^6 is selected from the group consisting of: hydroxy, C_{1-6} alkoxy and halogen;

R^7 is selected from the group consisting of: hydrogen, C_{1-6} aliphatic, hydroxy C_{1-6}-alkoxy, hydroxy-C_{1-6} aliphatic, C_{1-6} aliphatic carbonyl, Aryl-carbonyl, C_{1-12} alkoxyalkoxyalkoxyalkoxyalkyl, hydroxyl, Aryl, Aryl-C_{1-6}-alkoxy, Aryl-C_{1-6}-aliphatic, Het, Het-C_{1-6}-alkoxy, di-Het-C_{1-6}-alkoxy, Het-C_{1-6}-aliphatic and di-Het-C_{1-6}-aliphatic;

R^8 is trifluoromethyl;

Aryl is phenyl;

Cyc is cyclobutyl;

Het is a saturated or unsaturated heteroatom ring system selected from the group consisting of: benzimidazole, dihydrothiophene, dioxolane, furan, imidazole, morpholine, oxazole, pyridine, pyrrole, pyrrolidine, thiadiazole, thiazole, thiophene, and triazole;

and the salts, esters, amides, carbamates, solvates, polymorphs, hydrates, affinity reagents and/or prodrugs thereof.

36. A compound as claimed in any one of claims 1 to 35 in the form of a substantially pure E geometric isomer.

37. A compound as claimed in any one of claims 1 to 35 in the form of a substantially pure Z geometric isomer.

38. A compound as claimed in any one of claims 1 to 35 in the form of a mixture of E geometric isomer and Z geometric isomer in any proportions of said geometric isomers.

39. A compound as claimed in claim 1, in E, Z or E and Z form, selected from the group consisting of:

4-{[(2-Oxo-1,2-dihydro-3H-pyrrolo[3,2-c]pyridin-3-ylidene)methyl]amino}benzenesulfonamide;

4-{[(2-Oxo-1,2-dihydro-3H-pyrrolo[2,3-c]pyridin-3-ylidene)methyl]amino}benzenesulfonamide;

3-[(1H-Indazol-6-ylamino)methylidene]-1H-pyrrolo[3,2-b]pyridin-2-one;

3-[(6-Quinolinylamino)methylidene]-1,3-dihydro-2H-pyrrolo[3,2-b]pyridin-2-one;

4-{[(2-Oxo-1,2-dihydro-3H-pyrrolo[2,3-b]pyridin-3-ylidene)methyl]amino} benzenesulfonamide;

3-[(1H-Indazol-6-ylamino)methylidene]-1H-pyrrolo[2,3-b]pyridin-2-one;

3-[(6-Quinolinylamino)methylidene]-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one;

4-{[(2-Oxo-5-phenyl-1,2-dihydro-3H-pyrrolo[2,3-b]pyridin-3-ylidene)methyl]amino} benzenesulfonamide;

3-[(1H-Indazol-6-ylamino)methylidene]-5-phenyl-1H-pyrrolo[2,3-b]pyridin-2-one;

5-Phenyl-3-[(6-quinolinylamino)methylidene]-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one;

4-({[5-(2-Furyl)-2-oxo-1,2-dihydro-3H-pyrrolo[2,3-b]pyridin-3-ylidene]methyl}amino)benzenesulfonamide;

5-(2-Furyl)-3-[(1H-indazol-6-ylamino)methylidene]-1H-pyrrolo[2,3-b]pyridin-2-one;

5-(2-Furyl)-3-[(6-quinolinylamino)methylidene]-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one;

4-({[2-Oxo-5-(3-thienyl)-1,2-dihydro-3H-pyrrolo[2,3-b]pyridin-3-ylidene]methyl}amino)benzenesulfonamide;

3-[(1H-Indazol-6-ylamino)methylidene]-5-(3-thienyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one;

3-[(6-Quinolinylamino)methylidene]-5-(3-thienyl)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one;

4-{[(5-Bromo-2-oxo-1,2-dihydro-3H-pyrrolo[2,3-b]pyridin-3-ylidene)methyl]amino}benzenesulfonamide;

5-Bromo-3-[(1H-indazol-6-ylamino)methylidene]-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one;

5-Bromo-3-[(6-quinolinylamino)methylidene]-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one;

4-{[(6-Chloro-2-oxo-1,2-dihydro-3H-pyrrolo[2,3-b]pyridin-3-ylidene)methyl]amino}benzenesulfonamide;

6-Chloro-3-[(1H-indazol-6-ylamino)methylidene]-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one;

6-Chloro-3-[(6-quinolinylamino)methylidene]-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one;

Ethyl 3-{[4-(aminosulfonyl)anilino]methylidene}-2-oxo-1,2-dihydro-3H-pyrrolo[2,3-b]pyridine-5-carboxylate;

Ethyl 3-[(1H-indazol-6-ylamino)methylidene]-2-oxo-1,2-dihydro-3H-pyrrolo[2,3-b]pyridine-5-carboxylate; and

Ethyl 2-oxo-3-[(6-quinolinylamino)methylidene]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-5-carboxylate;

and the pharmaceutically acceptable salts, esters, amides, carbamates, solvates, affinity reagents and/or prodrugs thereof.

40. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 39 and one or more pharmaceutically acceptable carriers, diluents and/or excipients.

41. A method of inhibiting a kinase comprising the step of binding said kinase with the compound as claimed in any one of claims 1 to 39.

42. The method of claim 41 wherein the kinase is a mitogen activated protein kinase.

43. The method of claim 41 wherein the kinase is selected from the group consisting of: abl, ARaf, ATK, ATM, bcr-abl, Blk, BRaf, Brk, Btk, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, cfms, c-fms, c-kit, c-met, cRaf1, CSF1R, CSK, c-src, EGFR, ErbB2, ErbB3, ErbB4, ERK, ERK1, ERK2, Fak, fes, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, Fgr, FLK-4, Fps, Frk, Fyn, GSK, gsk3a, gsk3b, Hck, IGF-1R, IKK, IKK1, IKK2, IKK3, INS-R, Integrin-linkedkinase, Jak, JAK1, JAK2, JAK3, JNK, JNK, Lck, Lyn, MEK, MEK1, MEK2, p38, PDGFR, PIK, PKB1, PKB2, PKB3, PKC, PKCα, PKCβ, PKCδ, PKCε, PKCγ, PKCλ, PKCμ, PKCζ, PLK1, Polo-like kinase, PYK2, tie_1, tie_2, TrkA, TrkB, TrkC, UL13, UL97, VEGF-R1, VEGF-R2, Yes and Zap70

44. The method of claim 41 wherein the kinase is selected from the group consisting of: VEGF-R2, CDK1, CDK2, CDK3, Zap70, Lck and C-Fms.

45. The method of claim 41 wherein the kinase is VEGF-R2.

46. A compound as claimed in any one of claims 1 to 39 for use in therapy.

47. A method of treating a disease or disorder in an animal which comprises administering to said animal a therapeutically effective amount of a compound as calimed in any one of claims 1 to 39.

48. The method according to claim 47 wherein the compound or physiologically acceptable salt thereof is administered in an amount of from about 0.1 to about 100 mg/kg of body weight per day.

49. The method according to claim 47 wherein th compound or physiologically acceptable salt thereof is administered in an amount of from about 0.1 to about 10 mg/kg of body weight per day.

50. The method according to claim 47 wherein the animal is a human.

51. The method according to claim 47 wherein the disease or disorder comprises at least one condition selected from the group consisting of: organ transplant rejection, tumor growth, chemotherapy-induced alopecia, chemotherapy-induced thrombocytopenia, chemotherapy-induced leukopenia, mucocitis, plantar-palmar syndrome, restenosis, atherosclerosis, rheumatoid arthritis, angiogenesis, hepatic cirrhosis, glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy, glomerulopathy, psoriasis, diabetes mellitus, inflammation, neurodegenerative disease, macular degeneration, actinic keratosis and hyperproliferative disorders.

52. The method according to claim 47 wherein the disease or disorder comprises a viral or eukaryotic infection.

53. The method according to claim 47 wherein the disease or disorder comprises alopecia.

54. The method of claim 47 wherein the disease or disorder comprises at least one condition mediated by a kinase.

55. The method according to claim 56 wherein the kinase is as defined in any one of claims 42 to 45.

56. A method according to claim 47 wherein the compound is coadministered with one or more anti-cancer agents and/or treatments.

57. The use of a compound as claimed in any one of claims 1 to 41 in the preparation of a medicament for the treatment of a disease or disorder as defined in any one of claims 51 to 55.

58. A process for preparing a compound of formula (I) as claimed in claim 1 which process comprises one or more synthetic steps of any one of Schemes 1 to 6 as herein described.